Page 3 - Biofire Diagnostics News Today

/PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of...

The test received Emergency Use Authorization from the FDA in March 2021 and would be only the second COVID-19 test to receive FDA clearance.

/PRNewswire/ -- Global COVID-19 detection kits market value is projected to reach USD 6.1 billion by 2028, according to a new research report by Global Market...

Co-Diagnostics, Inc. (NASDAQ:NASDAQ:CODX) Q4 2021 Results Conference Call March 24, 2022 04:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - CEO Brian Brown - CFO...

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

The firm obtained FDA breakthrough device designation for an NGS approach to identify up to 400 bacterial pathogens used to diagnose sepsis and other bacterial infections.

COVID accelerated the development of cutting-edge PCR tests—and made the need for them urgent

Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.

The point-of-care molecular diagnostics market size to reach $5,381.18 million by 2028 from $2,230.94 million in 2021 to grow at a CAGR of 13.4% from 2021...

Clinical Comparison of Three Sample-to-Answer Systems for Detecting SARS-CoV-2 in B.1.1.7 Lineage Emergence